Research Papers:
miR-564 inhibits hepatocellular carcinoma cell proliferation and invasion by targeting the GRB2-ERK1/2-AKT axis
PDF | HTML | How to cite
Metrics: PDF 1758 views | HTML 2768 views | ?
Abstract
Chaojie Liang1,*, Yingchen Xu1,*, Hua Ge1, Bingchen Xing1, Guanqun Li1, Guangming Li1 and Jixiang Wu1
1Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Dongcheng, Beijing 100730, China
*These authors are contributed equally to this work
Correspondence to:
Jixiang Wu, email: [email protected]
Guangming Li, email: [email protected]
Keywords: miR-564; HCC; GRB2; PI3K/AKT; ERK1/2
Received: August 21, 2017 Accepted: October 28, 2017 Published: November 18, 2017
ABSTRACT
Recent studies have shown that miR-564 is closely related to the development of various tumors, including breast cancer, lung cancer and glioma. However, few studies have examined miR-564 in hepatocellular carcinoma (HCC). Here, we demonstrated that miR-564 expression in HCC tissues was lower than that in adjacent noncancerous tissues and that miR-564 expression was associated with tumor size, tumor number and vein invasion. Bioinformatics analyses showed that low levels of miR-564 were correlated with poor prognosis. Furthermore, upregulation of miR-564 impaired SMCC7721 and MHCC97H cell proliferation, migration and invasion in vitro and reduced tumorigenesis in vivo. Next, we found that GRB2 was a direct target gene of miR-564 in the HCC cell lines. GRB2 was highly expressed in HCC tissues and negatively correlated with miR-564 expression levels. When GRB2 was downregulated by GRB2-siRNA, HCC cell proliferation, invasion and metastasis were impaired, and restoring GRB2 expression partially reversed the inhibitory effects of miR-564. Western blot analysis showed that miR-564 overexpression reduced GRB2 expression in HCC cell lines and inhibited ERK1/2 and AKT phosphorylation. miR-564 overexpression also upregulated the epithelial-like cell marker E-cadherin and downregulated the interstitial cell-like markers N-cadherin and vimentin. These results suggest that miR-564 inhibits the malignant phenotype of HCC cells by targeting the GRB2-ERK1/2-AKT axis. Consequently, miR-564 may be used as a prognostic marker and therapeutic target for HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22504